Wandercraft's Eve exoskeleton receives FDA clearance for U.S. launch

The U.S. Food and Drug Administration (FDA) has cleared the commercial launch of Eve, a personal exoskeleton developed by the French company Wandercraft. Scheduled for release in the United States on September 17, the device is designed to provide upright mobility for adults with spinal cord injuries.

Eve is a self-balancing robotic suit that uses twelve motors located in the hips, knees, and ankles, alongside integrated sensors to maintain stability. Unlike previous models, it allows users to stand, walk, turn, and side-step without the need for crutches or walkers. The device is controlled via a joystick and is intended to complement, rather than replace, wheelchair use by enabling tasks such as standing to converse or performing daily activities at home.

The exoskeleton features a rigid vest design with supports for the torso, waist, thighs, legs, and feet, including a headrest and armrests. It has a maximum speed of 0.25 meters per second and a battery life of approximately four hours. In the event of power loss, a braking mechanism is designed to lower the user gradually to the ground.